The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database.
CHIC
age
hepatoblastoma
pediatric liver tumor
prognostic factor
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
06
07
2019
revised:
24
03
2020
accepted:
30
03
2020
pubmed:
10
5
2020
medline:
8
9
2020
entrez:
9
5
2020
Statut:
ppublish
Résumé
Treatment outcomes for hepatoblastoma have improved markedly in the contemporary treatment era, principally due to therapy intensification, with overall survival increasing from 35% in the 1970s to 90% at present. Unfortunately, these advancements are accompanied by an increased incidence of toxicities. A detailed analysis of age as a prognostic factor may support individualized risk-based therapy stratification. We evaluated 1605 patients with hepatoblastoma included in the CHIC database to assess the relationship between event-free survival (EFS) and age at diagnosis. Further analysis included the age distribution of additional risk factors and the interaction of age with other known prognostic factors. Risk for an event increases progressively with increasing age at diagnosis. This pattern could not be attributed to the differential distribution of other known risk factors across age. Newborns and infants are not at increased risk of treatment failure. The interaction between age and other adverse risk factors demonstrates an attenuation of prognostic relevance with increasing age in the following categories: metastatic disease, AFP < 100 ng/mL, and tumor rupture. Risk for an event increased with advancing age at diagnosis. Increased age attenuates the prognostic influence of metastatic disease, low AFP, and tumor rupture. Age could be used to modify recommended chemotherapy intensity.
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28350Informations de copyright
© 2020 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.
Références
Czauderna P, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014;26(1):19-28.
Aronson DC, Meyers RL. Malignant tumors of the liver in children. Semin Pediatr Surg. 2016;25(5):265-275.
Zsiros J, Brugieres L, Brock P, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013;14(9):834-842.
Aronson DC, Czauderna P, Maibach R, et al. The treatment of hepatoblastoma: its evolution and the current status as per the SIOPEL trials. J Indian Assoc Pediatr Surg. 2014;19(4):201-207.
Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000;18(14):2665-2675.
Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2. Eur J Cancer. 2004;40(3):411-421.
Hishiki T, Matsunaga T, Sasaki F, et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int. 2011;27(1):1-8.
Haberle B, Maxwell R, Schweinitz DV, et al. High dose chemotherapy with autologous stem cell transplantation in hepatoblastoma does not improve outcome. Results of the GPOH Study HB99. Klin Padiatr. 2019;231(6):283-290.
Meyers RL, Rowland JR, Krailo M, et al. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;53(6):1016-1022.
Roebuck DJ, Aronson DC, Clapuyt P, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 2007;37(2):123-132. quiz 249-150.
Aronson DC, Schnater JM, Staalman CR, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol. 2005;23(6):1245-1252.
Maibach R, Roebuck D, Brugieres L, et al. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. Eur J Cancer. 2012;48(10):1543-1549.
Czauderna P, Haeberle B, Hiyama E, et al. The Children's Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92-101.
Meyers RL, Maibach R, Hiyama E, et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncology. 2017;18(1):122-131.
López-Terrada D, Alaggio R, deDávila MT, et al. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol. 2013;27:472.
Ranganathan S, Lopez-Terrada D, Alaggio R. Hepatoblastoma and pediatric hepatocellular carcinoma: an update. Pediatr Dev Pathol. 2020 Mar-Apr;23(2):79-95.
Meyers RL, Tiao G, deVille de Goyet J, et al. Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr. 2014;26(1):29-36.
Haeberle B, Schweinitz D. Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies. Frontiers Biosci (Elite edition). 2012;4:493-498.
Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009;361(17):1662-1670.
Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol. 2010;28(15):2584-2590.
Sasaki F, Matsunaga T, Iwafuchi M, et al. Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: a report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg. 2002;37(6):851-856.
von Schweinitz D, Hecker H, Schmidt-von-Arndt G, et al. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer. 1997;74(6):593-599.
Katzenstein HM, Chang KW, Krailo MD, et al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer. 2009;115(24):5828-5835.
Malogolowkin MH, Katzenstein HM, Krailo MD, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol. 2006;24(18):2879-2884.
Towbin AJ, Meyers RL, Woodley H, et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol. 2018;48(4):536-554.
Kalbfleisch JDPR. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons; 1980.
Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma- results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer. 2000;36(11):1418-1425.
Allan BJ, Parikh PP, Diaz S, et al. Predictors of survival and incidence of hepatoblastoma in the paediatric population. HPB (Oxford). 2013;15(10):741-746.
Ammann RA, Plaschkes J, Leibundgut K. Congenital hepatoblastoma: a distinct entity. Med Pediatr Oncol. 1999;32(6):466-468.
Dall'Igna P, Brugieres L, Christin AS, et al. Hepatoblastoma in children aged less than six months at diagnosis: a report from the SIOPEL group. Pediatr Blood Cancer. 2017;00:e26791.
Trobaugh-Lotrario AD, Chaiyachati BH, Meyers RL, et al. Outcomes for patients with congenital hepatoblastoma. Pediatr Blood Cancer. 2013;60:1817-1825.
Buendia MA. Unravelling the genetics of hepatoblastoma: few mutations, what else. J Hepatol. 2014;61(6):1202-1204.
Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
Sumazin P, Chen Y, Trevino LR, et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology (Baltimore, MD). 2017;65(1):104-121.
Eichenmuller M, Trippel F, Kreuder M, et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol. 2014;61(6):1312-1320.